This Post Was Syndicated Under License Via QuoteMedia
Outcomes of several new studies to be released, demonstrating improved life with diabetes.
NEW YORK and CAESAREA, Israel, May 29, 2019 /PRNewswire/ — Global digital therapeutics (DTx) innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced its participation at the annual conference of the American Diabetes Association (ADA) in San Francisco on June 7th-10th.
At the ADA conference, Dario will publish several studies performed using de-identified data from thousands of users accumulated in its data base.
The studies demonstrate the benefits of Dario’s DTx solution to help improve life with diabetes and achieve clinically proven results.
The new studies emphasize the importance of in-range glucose management, not only as a key indicator of the long-lasting effectiveness of the Dario programs, but also as a major tool for each user to measure day after day how their body reacts to various foods, exercise and other stimuli.
Dario will also unveil several innovative components of its offering, including:
- A completely new Dario solution for hypertension
- An all-new approach to further increase user engagement
- Collection of detailed demographic information in its data base that will allow further personalization of the user experience and enable numerous analysis of the clinical data.
Please come and visit us at Booth #312 of the ADA Conference and look for the posters that will be presented!
Meanwhile, Dario is thankful for the enthusiastic response of its users: more than 5000 have rated Dario 4.9 stars out of 5 on the Apple store!
“Year after year, Dario has been presenting new studies at the ADA conference, demonstrating the effectiveness of well-designed digital therapies. Clinically proven results build credibility for digital interventions as an indispensable complement to pharmaceutical interventions or medical devices,” commented Olivier Jarry, President of DarioHealth.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way. Our Cross Functional Team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, when the Company states that the new studies demonstrate the benefits of Dario’s DTx solution to help improve life with diabetes and achieve clinically proven results, that the new studies emphasize the importance of in-range glucose management, not only as a key indicator of the long-lasting effectiveness of the Dario programs, but also as a major tool for each user to measure day after day how their body reacts to various foods, exercise and other stimuli and that clinically proven results build credibility for digital interventions as an indispensable complement to pharmaceutical interventions or medical devices, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Contact:
Joao Mendes-Roter
VP Marketing
[email protected]
347-767-4220
View original content to download multimedia:http://www.prnewswire.com/news-releases/dariohealth-to-present-new-evidence-of-digital-therapeutics-benefits-at-2019-american-diabetes-association-conference-300858123.html
SOURCE DarioHealth Corp.
